Introduction| Volume 7, SUPPLEMENT 1, S6-S7, December 2007

Download started.


Targeting the Right Target: Epidermal Growth Factor Receptor–Directed Individualized Therapy

      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Amado R
        • Wolf M
        • Freeman D
        • et al.
        Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy.
        Eur J Cancer. 2007; 5 (Abstract 7LB).: 8
        • De Roock W
        • De Schutter J
        • De Hertogh G
        • et al.
        KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab.
        J Clin Oncol. 2007; 25 (Abstract 4132).: 196s
        • Finocchiaro G
        • Cappuzzo F
        • Jänne P
        • et al.
        EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer.
        J Clin Oncol. 2007; 25 (Abstract 4021).: 168s
        • Khambata-Ford S
        • Garrett CR
        • Meropol NJ
        • et al.
        Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
        J Clin Oncol. 2007; 25: 3230-3237
        • Hecht R
        • Chidiac T
        • Mitchell E
        • et al.
        An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (Bev) for metastatic colorectal cancer (mCRC).
        Ann Oncol. 2007; 18 (Abstract 0-0033).: vii21
        • Van Cutsem E
        • Nowacki M
        • Lang I
        • et al.
        Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial.
        J Clin Oncol. 2007; 25 (Abstract 4000).: 164s
      1. Sobrero A, Fehrenbacher L, Rivera F, et al. Randomized phase III trial of cetuximab plus irinotecan vs irinotecan alone for metastatic colorectal cancer (mCRC) after failing prior oxaliplatin-based therapy: the EPIC trial. Presented at: 98th Annual Meeting of the American Association for Cancer Research; April 14-18, 2007; Los Angeles, CA.

        • Folprecht G
        • Grothey A
        • Alberts S
        • et al.
        Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.
        Ann Oncol. 2005; 16: 1311-1319